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Abstract 
 
Oculogyric crisis (OGC) describes the clinical phenomenon of sustained dystonic, 
conjugate and typically upward deviation of the eyes lasting from seconds to hours. It 
was initially observed in patients with postencephalitic parkinsonism, but since then a 
number of conditions have been associated with OGC. These include drug-induced 
reactions, hereditary and sporadic movement disorders, and focal brain lesions. Here, 
we systematically review the literature and discuss the spectrum of disorders associated 
with OGC in order to aid clinicians place this rare but distinctive clinical sign into the 
appropriate diagnostic context. We also provide a brief synthesis of putative 
pathophysiological mechanisms, as well as therapeutic recommendations based on the 
literature and our own experience.  
 
 
 
 
Introduction  
Oculogyric crisis (OGC) is a rare neurologic manifestation characterized by sustained 
dystonic, conjugate and typically upward deviation of the eyes lasting from seconds to 
hours [1]. Oculogyric crises were first described in patients with parkinsonism 
following the epidemy of encephalitis lethargica (Economo’s disease) during the 1910-
1930s [2]. Since then, OGCs have been reported in association with numerous 
conditions, as for example drug-induced, but also neurometabolic and 
neurodegenerative movement disorders, or as a consequence of focal brain lesions [3-
7].  
Although commonly reported as acute disorder, OGC may also occur within weeks or 
even months after an inciting event [1, 8-10]. Clinical presentation may vary from very 
brief and subtle eye deviation as an isolated symptom to more severe and even painful 
forms accompanied by neck flexion, jaw opening, blepharospasm, tongue protrusion 
and autonomic signs, such as perspiration, pupillary dilation, increases in blood 
pressure and heart rate. Episodes generally last minutes, but may range from seconds 
to hours. In addition, psychiatric symptoms such as agitation and anxiety, but also 
psychotic symptoms including visual, tactile and auditory hallucinatons, distortions of 
body schema, catatonic symptoms, mood disorders such as depression or mania and 
obsessive-compulsive behaviors may occur [3, 8, 11-14].  
Oculogyric crises are not life threatening. However, they often present a source of 
distress for patients and their environment. Due to their rarity and variable clinical 
severity OGCs may be easily overseen or misinterpreted as functional or as 
exacerbation of psychotic illness [11, 13]. Oculogyric crises are non epileptic eye 
movements and should, therefore, be distinguished from more commony occurring 
tonic eye deviations within the context of epileptic seizures (i.e. thorough history and 
clinical observation for features suggestive of an epileptic event and EEG), but also 
from oculogyric tics, as part of tics disorders [15, 16]. Oculogyric crises should also be 
separated from the paroxysmal tonic upgaze syndrome characterized by infantile-/early 
childhood-onset and episodic tonic upward deviation of the eyes, neck flexion 
downbeating saccades in attempted downgaze and normal horizontal eye movements 
[17]. Indeed, the recognition of OGCs is a useful clinical sign to guide the diagnostic 
procedure, leading in turn to appropriate counceling and treatment. To date, there has 
been no systematic study to assess the spectrum of conditions reported to occur with 
OGCs and to provide a list of relevant diagnoses in such cases.  
 
Methods  
This review is based on a systematic search of the literature in PubMed (a service of 
the National Library of Medicine’s National Center for Biotechnology Information; 
http://www.ncbi.nlm.nih.gov) for all publications up to March 2016 using the key 
words oculogyric eye movements, oculogyric crisis/crises, tonic eye deviation, tonic 
gaze deviation and all combinations of these. Only articles with publication of original 
clinical information and published in English were considered. Pertinent references 
cited in relevant articles and their bibliographies were also checked and considered if 
fulfilling the criteria for this review. After removal of articles without abstract, 
duplicates and opinions/comments about articles, all abstracts and full texts if available 
were reviewed. Articles without original, insufficient or inconsistent clinical 
information were excluded. All identified articles are referenced in supplement 1. 
 
Results 
According to our inclusion and exclusion criteria 147 publications reporting the clinical 
characteristics of 394 patients with OGCs were identified. Based on our results, three 
main aetiological categories were discerned: 1. Drug-induced OGCs; 2. Oculogyric 
crises associated with hereditary and sporadic movement disorders; 3. Oculogyric 
crises as a result of focal brain lesions. Following, we present the clinical characteristics 
of patients of these three categories according to their reported frequency. Based on 
these data we also provide a synthesis of putative pathophysiological mechanisms and 
present recommended treatment strategies. 
  
1. Drug-induced OGC 
The majority of the reported OGC cases were drug-induced, most commonly as adverse 
effects of neuroleptics, antiemetics or other dopamine antagonists (complete list of 
drugs inducing OGCs is provided in table 1). Among the 175 reported patients the 
median age was 22 years (range: seven months to 54 years), with a 1:1 male/female 
ratio. Oculogyric crises usually disappeared within 24 to 48 h upon withdrawal or 
reduction of the antidopaminergic/neuroleptic medication. 
 
Neuroleptics 
Sixtyeight percent of all reported patients (median age: 24 years; range: five to 47 years) 
with drug-induced OGCs we could identify were due to neuroleptics. In this context 
OGCs were commonly described as an acute dystonic reaction usually occurring 
promptly after the administration, or less often, following long-term exposure to 
neuroleptics (i.e. OGC as a tarvide dystonic reaction) [8, 18]. Both typical and atypical 
neuroleptics induced OGCs, however the use of typical neuroleptics and OGCs was 
more commonly reported (63 patients in 15 articles for typicals versus 32 patients in 21 
articles for atypicals; the exact neuroleptic agent was not reported for 24 remaining 
cases). Younger age, male sex, dose increase of an existing pharmacological agent or 
the introduction of a new agent were reported as associated risk factors [19-22]. 
 
Antiemetics 
We found nine articles reporting OGCs in ten female patients and one male patient 
(median age: 21 years; range: 13 to 55 years) receiving antiemetics. Oculogyric crises 
were reported in five patients following intake of metoclopramide [23-27], in three 
patients upon administration of phenothiazines [28] used as antiemetics, and also in 
single cases associated with intake of clebopride, ondansetron and droperidol [29-31].  
 
Anticonvulsants 
Thirteen patients in seven different articles were identified reporting OGCs as a result 
of treatment with anticonvulsants. The five male and five female patients (the gender 
of the remaining three patients was not reported) had a median age of 26 years (range: 
three to 33 years). Carbamazepine (six patients) [32-35], lamotrigine (four patients) 
[36], gabapentin (two patients) [37], and oxcarbazepine (one patient) [38] are described. 
All patients were treated for epilepsy with or without mental retardation. In most 
patients OGCs were terminated by dose reduction suggesting a dose-depending effect 
[33, 34, 36]. 
 
Antidepressants  
Oculogyric crises were also reported in association with antidepressants (four articles, 
three female and one male patients; median age: 28 years; range: ten to 44 years). Three 
articles reported OGCs following intake of selective serotonine reuptake inhibitors 
(SSRIs; fluoxetine and citalopram, fluvoxamine, escitalopram) [39-41]. One article 
reported the induction of OGCs by imipramine, one of the first tricyclic antidepressants 
acting by inhibiting serotonine and noradrenaline reuptake [42]. 
 
Others 
Further case reports and case series (13 articles, 24 patients; median age: 15 years; 
range: seven months to 54 years) described OGCs after intake of cetirizine (number of 
patients; n=9) [43], organophosphate poisoning (n=3) [44], tetrabenazine (n=2) [45, 46], 
L-dopa (n=2) [47], lithium (n=1) [48], tensilon (n=1) [49], cefexime (n=1) [50], 
pentazocine (n=1) [51], nifedipine (n=1) [52], isotretinoin (n=1) [53], phencyclidine 
(n=1) [54] and salicylate intoxication (n=1) [55].  
 
 
OGC despite withdrawal or following discontinuation of medication 
Oculogyric crises usually disappear within 24 to 48 h upon withdrawal or reduction of 
the triggering agent; and continuation of OGCs without further exposure is generally 
not seen.  
Schneider and collegues, however, observed OGCs in three patients in whom episodes 
of OGCs, initially triggered by a single dose of haloperidol (in two cases) or a single 
dose of metoclopramide (in one case), continued spontaneously despite withdrawal [9]. 
Oculogyric crises in these cases were successfully treated with anticolinergics.  
On the other hand, Mendhekar and Duggal described a female patient with mental 
retardation and aggressive behavior who developed OGCs only after abrupt 
discontinuation of clozapine. This resolved upon recommencing the medication [56]. 
Oculogyric crises have also been described during off-periods of L-dopa treatment in 
two parkinsonian patients, which improved with increasing the dopaminergic 
medication [57, 58].   
 
2. Hereditary and sporadic movement disorders 
The second most common association of OGCs was with hereditary and sporadic 
movement disorders (complete list of all disorders is provided in table 2). In total 57 
articles with 207 patients were identified with a median age of 23 years (two months to 
92 years) and 1:1.3 male/female ratio (64 males, 83 females; 60 patients no gender 
reported).  
 
Disorders of dopamine metabolism  
Disorders of dopamine metabolism are the most common metabolic cause of OGCs, 
which may be a clue towards the pathophysiology (see below). The literature review 
revealed 103 cases (in 28 reports). This included deficiency of aromatic L-amino acid 
decarboxylase (AADC) (n=75 in 17 articles)[59-61], sepiapterin reductase (SR) [62-
65] (n=19; median age: 10 years; range: three to 23 years), tyrosine hydroxylase (TH) 
[66-70] (n=7) and guanosine-triphophate cyclohydrolase type I (GTPCH) [71] (n=1) or 
moleculary-undefined dopa-responsive dystonia (n=1) [72], all autosomal-recessive 
disorders with similar phenotypic features [4]. In more detail, for AADC, reported 
patients were mostly infants and children (median age: five years; range: two months 
to 33 years) and presented with early (neonatal) hypotonia, developmental delay, 
autonomic abnormalities, such as excessive sweating or temperature instability and 
OGCs. Associated movement disorders included parkinsonism, dystonia and/or chorea.  
 
Other hereditary movement disorders 
Oculogyric crises were reported in 22 female patients with Rett syndrome [73], six 
patients (median: nine years; range: three to 16 years) with mutations at the SLC18A2 
gene encoding the vesicular monoamine transporter 2 (VMAT2) in the presynaptic 
neurons [74, 75] and three cases of Kufor Rakeb disease due to mutations in ATP13A2 
[76, 77]. Further, OGCs were described in two cases with neuronal intranuclear 
inclusion disease (NIID) [78, 79]. Oculogyric crises have also been associated with 
neurodegeneration with brain iron accumulation due to mutations in PLA2G6 [80] and 
pantothenate kinase-associated neurodegeneration (PKAN) [81].Interestingly, in the 
two cases of PLA2G6 neurodegeneration with brain iron accumulation, OGCs occurred 
in the dopaminergic ON state, and this has been suggested as a helpful clinical hint to 
differentiate this type of disorder from other brain iron accumulation syndromes[80].  
 
Pathogenic mutations in GRIN I gene, encoding for the GluN1 subunit of the ionotropic 
glutamate N-methyl-D-aspartate (NMDA) are associated with an early onset 
dysmorphic syndrome, oculomotor abnormalities, epilepsy, spasticity and hyperkinetic 
movement disorders, to include chorea and myoclonus [82]. MRI images show 
structural abnormalities such as ventriculomegaly, thin corpus callosum and cerebral 
atrophy. Oculogyric crises have been described in two such cases [82].  
Furthermore, single cases of OGCs were described in hypomyelination with atrophy of 
the basal ganglia and cerebellum (H-ABC) syndrome [83], rapid-onset dystonia 
parkinsonism due to mutations in the ATP1A3 gene [84], Perry syndrome [85], 
Wilson’s disease [5], Chédiak-Higashi syndrome [86] and ataxia-telengiectasia [87]. 
Also, OGCs were described in a patient with molecularly unclassified juvenile 
parkinsonism [88].  
 
Sporadic movement disorders 
Oculogyric crises in sporadic movement disorders were identified in 15 articles 
describing 59 patients. The majority of the identified articles reported OGCs in 
parkinsonian patients (number of patients: n=54; median age: 35 years; range: eight to 
92 years), as a result of encephalitis lethargica (EL) (n=48) [14, 89-94], EL-like illness 
(n=1) [95] or Japanese Encephalitis (n=1) [96]. Oculogyric crises were further reported 
in patients with young-onset (n=1) [97] and juvenile onset parkinsonism (n=2)[88, 98], 
and due to subcortical arteriosclerotic encephalopathy (n=1) [99]. Blepharospasm (n=4) 
[100] and non-wilsonian hepato-cerebral degeneration (n=1) [101] were also associated 
with OGCs. Movements described as OGCs have also been more recently described in 
patients with functional movement disorders [102]. 
 
3. Focal brain lesions:  
Twelve single case reports of OGCs occurring as a result of focal brain lesions were 
also identified. They included lesions of the brainstem caused by herpetic encephalitis 
[7], the dorsal midbrain area (mesencephalic locomotor region) [103], the substantia 
nigra [6], the posterior third ventricle affected by a cystic glioma [104] and the basal 
ganglia [105, 106], [107]. Also two patients with either multifocal drug-induced 
encephalopathy or posterior leukencephalopathy syndrome were reported to develop 
OGCs [108, 109]. However, in both of these cases additional factors may have 
contributed to the development of OGCs. Finally, OGCs have also been reported most 
likely in association with focal lesions caused by neurosyphilis and multiple sclerosis 
[110]. 
 
Pathophysiology 
 
The pathophysiology of OGCs remains elusive. However, despite the numerous 
conditions associated with OGCs and the diversity of clinical presentations, there 
appear to be common pathophysiological changes associated with the manifestation of 
OGCs. First, in all reviewed cases where OGCs were clearly a result of focal brain 
lesions, damage was reported either to the basal ganglia or the midbrain, and thereby 
related to possible anatomical disruption of the nigrostriatal pathway. Second, most 
agents related to drug-induced OGCs (e.g. neuroleptics or antiemetics) 
characteristically lead to a functional disruption of dopaminergic neurotransmission. 
Third, most of the hereditary and sporadic movement disorders associated with OGCs 
are also directly related to either neurochemical (e.g. AADC and others [4]) or 
anatomical disruption of dopamine synthesis (e.g. through lesions or gliosis as for 
example in postencephalitic parkinsonism [111], Wilson’s disease [5] or Perry 
syndrome [85]) and typically manifest with parkinsonian and/or dystonic symptoms. It, 
thus, appears that dopaminergic neurotransmission is at the pathophysiological 
epicentre of OGCs.  
 
Considered within the frame of dystonic reactions (also referred to as “extraocular 
muscle dystonia” [100], it has been often proposed that OGCs, as other acute drug-
induced dystonias, could be the result of an imbalance between dopaminerigc and 
cholinergic inputs within the striatum. Indeed, striatal dopaminergic input is known to 
suppress cholinergic tone [112, 113]. Dopaminergic hypofunction, particularly related 
to striatal dopamine D2 receptors of cholinergic interneurons, could lead to a relative 
increase of cholinergic neurotransmission within the striatum and alterations in 
excitation properties of medium spiny neurons leading to dystonic symptoms, including 
OGCs [114]. Clinical knowledge also lends support to this hypothesis, as 
anticholinergic drugs often lead to an amelioration of OGCs.  
 
However, an imbalance between dopaminergic and cholinergic neurotransmission may 
not be the sole pathophysiological explaination for all OGC cases. For example, the 
pathophysiology of tardive OGCs, as of other tardive dystonic syndromes, might be 
different and more complex. Hypersensitivity of striatal dopamine receptors due to 
chronic dopamine receptor blockage, neurodegeneration of striatal interneurons, as well 
as dysfunction of striatal gamma-Aminobutyric acid (GABA)-ergic interneurons and 
more recently the hypothesis of maladaptive synaptic plasticity have been proposed to 
explain the presence of tardive involuntary movements [115]. However, robust 
experimental data, including animal models of OGCs, to support either hypothesis in 
humans are lacking. Moreover, it is unclear, whether tardive OGCs share similar 
pathophysiological properties with other tardive syndromes, such as tardive dystonia.  
 
Similarly, the pathophysiology of OGCs related to drugs, not directly associated with 
dopaminergic function, as for example SSRIs also remains unclear. Several hypotheses 
have been put forward, including hyperstimulation of 5-HT2 receptors, inhibition of 
dopaminergic and alteration of cholinergic and GABAergic activity [116-118]. Indeed 
these hypotheses have been linked to SSRI-induced dystonic reactions. However, most 
of these hypotheses are not supported by direct experimental data in humans, nor 
specifically address OGCs.  
 
Taken together, although the vast majority of conditions associated with OGCs are 
related with dopaminergic dysfunction, in the absence of direct experimental data, 
hypotheses regarding the origin of OGCs remain speculative.  
 
Treatment 
 
Treatment strategies are variable and depend on the aetiology of OGCs. In drug-
induced OGCs the first step of management should include removing or, if not possible, 
reducing the dose of the offending agent [10, 119]. In acute cases, administration of 
anticholinergics, such as benztropine (e.g. 2mg intravenous) and biperiden (e.g. 5mg 
intramuscular) or antihistaminics, such as diphenhydramine can lead to symptom 
alleviation within minutes. If response is lacking drug administration should be 
repeated after 15-30 minutes [119-122]. To avoid re-occurance of symptoms over the 
ensuing time frame oral administration of anticholinergics for at least 4-7 days is 
recommended [119]. Oral administration of anticholinergics may be the most feasible 
approach for cases seen outside the emergency setting. In cases of persistent lack of 
response oral treatment with benzodiazepines such as clonazepam (e.g. 0.5-4 mg) might 
provide symptom relief [123].  In cases of tardive OGCs the aforementioned agents 
might be insufficient and long-term treatment with (atypical) neuroleptics such as 
clozapine might be required [124, 125]. However, it should be noted that treatment 
effects might be limited in tardive OGCs, as substances such as clozapine themselves 
may also cause OGCs [126-128].  
 
Treatment of OGCs with L-dopa may also be successful in patients with parkinsonism 
including idiopathic Parkinson’s disease with OGCs related to wearing off [57, 58]; but 
also in other conditions such as Kufor Rakeb disease [76], NIID [78] and PKAN-
associated neurodegeneration [81]. Of note, administraton of L-dopa has been reported 
to elicit OGCs in patients with parkinsonism as peak-dose phenomenon and hence some 
caution is advised[47]. Although L-dopa is benefitial in postencephalitic parkinsonism, 
the presence of drug-induced dyskinesias in these patients limits therapeutic success 
[14]. Benztropine has also been reported to alleviate symptoms in patients with EL-like 
illness [95].  
 
In OGCs associated with focal brain lesions (e.g. striatocapsular infarction [105], 
pallidonigral lesion [6], lentiform nuclei [107]) the use of anticholinergics has been 
reported beneficial. Single cases have highlighted the use of antihistaminics 
(ondansetron-induced encephalopathy [108] and posterior leukencephalopathy 
syndrome [109]) and carbamazepin [103] in treatment of OGCs episodes. 
 
Conclusion and future directions 
The spectrum of conditions associated with OGCs is wide and encompasses three main 
caterogories of disorders: 1. drug-induced disorders, 2. hereditary and sporadic 
movement disorders, 3. disorders related to focal brain lesions.  The common basis of 
these disorders is a metabolic, anatomical or functional disruption of the nigrostriatal 
pathway, mainly of dopamine metabolism. Treatment should be causal where possible 
(i.e. removal of triggering factors; avoidance of further exposure). In the acute phase 
restoration of the imbalanced neurotransmitters using anticholininergics can provide 
rapid improvement. In-depth understanding of the pathophsyioligical mechanisms is 
lacking.  
 
Indeed, the systematic analysis of the data presented here also revealed several 
knowledge gaps pertaining to clinical and pathophysiological aspects of OGCs. There 
is large heterogeneity in the clinical presentations of OGCs between patients and 
conditions, but this remains largely underexplored and, therefore, poorly understood. 
While attempts have been made to delinate differences between associated phenomena, 
such as psychiatric and autonomic symptoms in some of the conditions presenting with 
OGCs [11], this has been  based on retrospective literature reviews and there are no  
studies systematically characterizing prospective pharmacogenetic and clinical features. 
Hence, to date, no predictors have been identified regarding which patients could be 
susceptible to developing OGCs, under which conditions and how severe their clinical 
manifestations might be. Also, there are no well-established treatment 
recommendations for patients who fail to respond to first-line drugs. Paucity of 
systematic clinical data makes it challenging to pinpoint concise pathophysiological 
mechanisms of OGCs. Indeed, although our systematic review provides evidence that 
both the dopaminergic and cholinergic system are involved in the pathophysiology of 
OGCs, the exact mechanisms, including functional neuroanatomic and 
neuropharmacologic underpinnings, remain elusive. Animal models, alongside 
neuropathologic case studies, as well as in-vivo high-resolution structural and 
functional neuroimaging will be helpful to shed further light on these matters. Indeed, 
addressing the aforementioned questions will inevitably lead to better patient care. 
Importantly, it will also expand our understanding beyond the narrow 
pathophysiological framework of OGCs by providing information on the interplay 
between dystonic (oculmomotor) symptoms with psychiatric and autonomic 
phenomena. The number of different etiological conditions with partially overlapping, 
but distinct pathophysiologies we provide here is a first step towards understanding the 
pathophysiology behind OGCs and their associations.  
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